- 1、本文档共6页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
膀胱癌有利文章
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Carlo Piccinni, PHD , Domenico Motola, PHD
Diabetes Care June 2011 vol. 34 no. 6 1369-1371
Abstract
OBJECTIVE To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications.
RESEARCH DESIGN AND METHODS Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR).
RESULTS Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82–6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively).
CONCLUSIONS In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issueneeds constant epidemiologic surveillance and urgent definition by more specific studies.
A link between pioglitazone and bladder cancer first appeared in preclinical studies and was first reported on the U.S. pioglitazone label in 1999, but experimental studies recently suggested that it might be a rat-specific phenomenon (1). In the large PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study, 14 bladder cancers occurred in the pioglitazone arm (0.5%) versus 6 in the placebo arm (0.2%) (2,3), and in September 2010, the U.S. Food and Drug Administration (FDA) announced an ongoing investigation on the possible risk in humans (4). Accordingly, the drug manufacturer is conducting a 10-year observational study to address the long-term risk of bladder ca
您可能关注的文档
- 2014年FDA批准的31个移动医疗产品详情分析.doc
- 4.25全国儿童预防接种宣传日 宣传资料.doc
- 欧盟防伪指令2011 62 EU(中英文).doc
- 中英文通风空调施工方案.doc
- 食品客户审核细则英文版.doc
- 实训八:控制菌(大肠埃希菌)检查操作规程.doc
- 精神病药物阿立哌唑的作用机理.doc
- CSJ-D中英文对照.doc
- Cobit高分题目汇总.docx
- 关于猪场用药的一些知识.doc
- 万有引力定律(第二课时)课件-高一下学期物理人教版.pptx
- 2024_2025学年新教材高中生物第4章生物技术的安全性与伦理问题课前自主预习案学案新人教版选择性必修第三册.docx
- 2024_2025学年新教材高中物理第一章运动的描述第3节位置变化快慢的描述__速度学案新人教版必修第一册.doc
- 金沙遗址欢迎你放映版.pptx
- 2025年中国腰形扣钉扣机市场调查研究报告.docx
- 贴身衣物我会洗(课件)-五年级下册劳动皖教版.pptx
- 2024_2025学年新教材高中英语Unit2BesportybehealthyS3课后巩固练习含解析译林版必修第二册.doc
- 2025年中国腹背锻炼器市场调查研究报告.docx
- 2024_2025高中物理第二章匀变速直线运动的研究第6节伽利略对自由落体运动的研究3作业含解析新人教版必修1.doc
- 2025年中国腺嘌呤磷酸盐市场调查研究报告.docx
文档评论(0)